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C
hronic hepatitis B virus (HBV) infection has a much
greater impact globally than in the US, yet even in the
relatively low-prevalence US population, 1.25 million people are
chronically infected, and an estimated 15–40% of those develop
cirrhosis.
1–3 Chronic HBV is less prevalent in the US than
hepatitisCvirus(HCV)infection,
4butthelikelihoodthatpatients
with HBV will die from liver-related disease is much higher than
with HCV.
3 Furthermore, HBV has four phases of infection and a
more variable natural history, with nonlinear, alternating pro-
gressionofdiseasestages,
5 makinglong-termmanagementmore
complex and labor intensive. The modern era of HBV manage-
ment now includes the use of quantitative tests of HBV DNA
in initial diagnostic and routine long-term management,
6
and the potential use of any of seven currently available
HBV treatments.
5 Although screening for HBV and appro-
priate vaccination for HBV still need increased attention and
implementation,
7 patients with established chronic HBV
need lifelong monitoring, and this will generally be done in
the primary care setting.
Publishedclinicalguidelines,suchasthosefromtheAmerican
Association for the Study of Liver Diseases (AASLD),
5 the US
TreatmentAlgorithm,
8andtheNIHConsensusConference,
9offer
recommendations as to the frequency of monitoring of ALT, HBV
DNA,andHBeAgfordifferentsubgroupsofchronicHBVpatients.
They also give recommendations as to when to initiate antiviral
HBV treatment and guidelines as to the choice of drug or
combination or drugs. Unfortunately there are several problems
with these recommendations. For one, the recommendations are
quite complicated. For example, for patients who are HBeAg
positive and have ALTone to two times the upper limit of normal,
the AASLD recommends monitoring the ALTevery 3 months and
monitoring the HBeAg every 6 months. However, if the patient is
HBeAg positivebut the ALTislessthanthe upperlimit ofnormal,
then they recommend monitoring the ALTevery 3–6m o n t h sa n d
monitoring the HBeAg every 6–12 months. For patients who are
HBeAg negative with an ALT one to two times the upper limit of
normal and HBV DNA between 2,000–20,000 IU/ml, they
recommend checking the ALT every 3 months and the HBV
DNA every 3 months.
5 The purpose of this frequent monitoring is
to determine when a patient may be transitioning from active to
inactive phases of disease or vice versa, or when a patient would
become eligible for antiviral treatment. However, the second and
more significant problem with these guidelines is that there are
no data to support the recommended frequencies for laboratory
monitoring.WhileitisincreasinglyevidentthatALTelevationand
HBV DNA level are strong predictors of development of cirrhosis
and HCC,
10–12 the recommendations for indefinite monitoring of
ALT, DNA, and HBeAg every 3 or 6 months have never been
studied in any randomized trial or been compared to other
frequencies, and there are no data to show that such frequent
monitoring leads to an increased use of antiviral treatment or a
mortalitybenefit.Thethirdproblemwiththecurrentguidelinesis
that long-term management with this frequency of complex
monitoringisanambitiouschargeforprovidersandpatients.The
intensity of the schedule requires a significant burden of
both time and resources for both providers and patients.
Finally, as for the guidelines for the use of treatment of HBV,
while there are clinical trials to support benefits and safety
of each therapy or combination of therapies, the endpoints
in HBV treatment trials have largely been surrogate mar-
kers, such as suppression of HBV DNA, normalization of
ALT, and seroconversion of HBeAg to anti-HBe. However, to
date, no randomized controlled trials of anti-HBV therapies
have demonstrated a beneficial impact on overall mortality,
liver-specific mortality, or development of HCC.
InthisissueofJGIM,twoimportantpapers(byJudayetal.and
Shamliyan et al.) highlight two different but related questions
needing attention in HBV management for general internal
medicine.Judayandcolleagues
13reportonaretrospectivecohort
study examining whether US patients with chronic HBV are
receiving laboratory monitoring of ALT and/or HBV DNA as
guidelines recommend. The authors utilized a US health care
claims database of almost 1,200 patients to investigate what
proportion of chronic HBV patients had claims for ALT and/or
HBV DNA monitoring. The authors looked for laboratory moni-
toringtohavebeenperformedatleastonceina12-monthperiodto
assess adherence to clinical guidelines. They found that ALT
monitoring is performed much more frequently than HBV DNA
monitoring,andthatifDNAmonitoringisperformed,mostlyALTis
performed as well. But since only 35% of patients had been
monitored in the year, this demonstrates the low implementation
of the monitoring recommendations. Since annual laboratory
monitoring is much less intensive than what some of the guide-
lines actually recommend, these results show an adherence rate
thatisactuallyhigherthanitwouldbeiftheauthorslookedforthe
every 3 months as recommended by some guidelines for the more
activesubgroupsofHBVpatients.Whatthestudydoesnotanswer
is whether such monitoring is beneficial. It begs the question,
though, that if this population has approximately two thirds of the
patients not being monitored at all in 1 year, will monitoring four
times as often, up to every 3 months, as somegroups recommend,
ever be reasonable to expect? And more importantly, is the effort
and cost for such monitoring actually worthwhile? These ques-
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232tions still need to be answered if we are going to aim to adhere to
such guidelines for long term management.
Also in this issue, Shamliyan and colleagues
14 present a
systematic review on the comparative effectiveness of anti-
viral treatments for chronic HBV. The authors show that
there is no high quality evidence of the effects of antiviral
HBV drugs on clinical outcomes. The study provides
clinicians with needed comparative effectiveness data of
hepatitis B treatments, but from clinical trials that are
based on intermediate outcomes. Should we abandon HBV
treatment since there are no data to show these desired
outcomes? It is hard to justify completely holding off on
using treatments that are available and show improvement
in these intermediate markers, but future clinical trials
should incorporate longer term outcomes to align treatment
with the surrogate markers and whether the surrogate
markers reflect important clinical outcomes.
It is true that primary care providers are not well enough
informed about HBV monitoring and treatment. In 2010 the
Institute of Medicine reported
15 on the knowledge gap that exists
in primary care on the subject of viral hepatitis and urged for this
knowledge gap to be addressed. The primary care provider has the
opportunity to have enormous impact on HBV by appropriately
screening and identifying unknown infections, preventing trans-
mission through education and targeted vaccination, and reduc-
ingthelikelihoodoftheprogressionofliverdiseasebecauseofHBV
by counseling on alcohol reduction. Both papers in this issue
13,14
provide much needed information on HBV, while at the same
time, they both also highlight that before we aim to monitor
patients intensively for the purpose of capturing them at the
time that is best for treatment, we first need better evidence
about whether frequent monitoring increases the use of
treatment and whether HBV treatments provide benefit in
progression to cirrhosis, HCC, and mortality. As we continue
to make advances in the care of patients with hepatitis B, we
must ask for the data behind the guidelines before we decide
the guidelines are right for us.
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